Pulnovo Medical has announced the first enrolment in Malaysia and Singapore for its global clinical study of percutaneous pulmonary artery denervation (PADN) technology, aimed at treating pulmonary hypertension (PH) associated with left heart disease.
PADN is a percutaneous pulmonary artery intervention procedure is a procedure that employs a PADN catheter to deliver radiofrequency energy to the sympathetic nerves on the outer membrane of the pulmonary artery. This treatment removes the myelin sheath of these nerves and causes the axons to fuse, thereby reducing sympathetic activity.
The procedure is designed to enhance cardiac output, lower pulmonary artery pressure, and prevent pathological changes in the pulmonary arteries. It also aims to improve exercise tolerance and cardiac function, potentially offering long-term benefits from a single minimally invasive intervention.
In Malaysia, Dr Ong Tiong Kiam, Director of Sarawak Heart Centre, Dr Alan Fong, Chairman of the National Cardiovascular Society, and Dr Koh Keng Tat successfully performed the PADN procedure.
The company reported that the procedure went smoothly, with the PADN technology demonstrating excellent performance and effectively complementing the medical team’s expertise.
Pulnovo Medical stated: “The successful completion of this clinical procedure has also reinforced the positive trend observed in clinical data, showcasing the seamless integration of PADN technology with the latest innovations.
“Post-enrolment, clinical parameters indicated strong outcomes, with significant improvements in patient data. This achievement sets a new milestone for the global expansion and application of PADN technology.”
In Singapore, the initial procedure was supervised by Professor Chen Shaoliang of Nanjing Hospital, affiliated with Nanjing Medical University. It was carried out at the National Heart Centre of Singapore by Dr Lim Soo Teik, Dr Jonathan Yap, and their team.
Last month, Pulnovo Medical announced the first enrolment in Portugal for the same global clinical study. The company had reported the successful initiation and enrolment of two patients at Centro Hospitalar Universitário de Lisboa Central – Hospital de Santa Marta in Portugal.
